Discovery of a first-in-class reversible DNMT1-selective inhibitor

被引：0
|
作者：
Pappalardi, Melissa B. [1 ]
机构：
[1] GlaxoSmithKline, Collegeville, PA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3265
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-class: RGS protein inhibitor
    Kimple, A. J.
    Siderovski, D. P.
    MOLECULAR INTERVENTIONS, 2007, 7 (01) : 9 - 9
  • [22] Lenacapavir: a first-in-class HIV-1 capsid inhibitor
    Dvory-Sobol, Hadas
    Shaik, Naveed
    Callebaut, Christian
    Rhee, Martin S.
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 15 - 21
  • [23] Discovery of first-in-class highly selective TRPV1 antagonists with dual analgesic and hypoglycemic effects
    Liu, Chunxia
    Wang, Wenxin
    Zhao, Shiyu
    Chen, Siliang
    Chen, Haoyang
    Wang, Suhua
    Li, Zheng
    Qian, Hai
    Tian, Xin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 107
  • [24] Fostemsavir: a first-in-class HIV-1 attachment inhibitor
    Grant, Philip M.
    Kozal, Michael J.
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 32 - 35
  • [25] The discovery of first-in-class drugs: origins and evolution
    Jörg Eder
    Richard Sedrani
    Christian Wiesmann
    Nature Reviews Drug Discovery, 2014, 13 : 577 - 587
  • [26] Discovery of Covalently-bound, First-in-Class Allosteric Inhibitor of PRMT5
    McKinney, D.
    Ranaghan, M.
    McMillan, B.
    Brousseau, M.
    O'Keefe, M.
    Moroco, J.
    Singh, R.
    Besnik, B.
    McCarren, P.
    Mulvaney, K.
    Sellers, W.
    Ianari, A.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S1 - S1
  • [27] The discovery of first-in-class drugs: origins and evolution
    Eder, Joerg
    Sedrani, Richard
    Wiesmann, Christian
    NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (08) : 577 - 587
  • [28] Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer
    Zhang, Bin
    Zhu, Chengchen
    Chan, Albert S. C.
    Lu, Gui
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 256
  • [29] Discovery of TAK-243: An investigational, first-in-class inhibitor of the ubiquitin activating enzyme
    Ciavarri, Jeffrey
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [30] Discovery of a first-in-class CDK2 selective degrader for AML differentiation therapy
    Liguo Wang
    Xuejing Shao
    Tianbai Zhong
    Yue Wu
    Aixiao Xu
    Xiuyun Sun
    Hongying Gao
    Yongbo Liu
    Tianlong Lan
    Yan Tong
    Xue Tao
    Wenxin Du
    Wei Wang
    Yingqian Chen
    Ting Li
    Xianbin Meng
    Haiteng Deng
    Bo Yang
    Qiaojun He
    Meidan Ying
    Yu Rao
    Nature Chemical Biology, 2021, 17 : 567 - 575
12345